UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 195

Sortiert nach

Abstract 1092: Alterations of the retinoblastoma gene in stage III breast cancers

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.1092-1092

2010

Volltextzugriff (PDF)

Abstract 1792: MDM2 promoter variants and mRNA expression in irradiated lymphocytes

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1792-1792

2013

Volltextzugriff (PDF)

Abstract 3704: Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension in a single-arm Phase II study

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3704-3704

2012

Volltextzugriff (PDF)

Abstract CT010: Efficacy results based on PIK3CA status in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT010-CT010

2017

Volltextzugriff (PDF)

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Oncotarget, 2017-06, Vol.8 (25), p.41227-41241

2017

Volltextzugriff (PDF)

Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors

Human gene therapy, 2002-06, Vol.13 (9), p.1115-1125

2002

Volltextzugriff (PDF)

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2444-2447

2006

Volltextzugriff (PDF)

Alterations in the insulin-like growth factor system during the menstrual cycle in normal women

Maturitas, 1998-01, Vol.28 (3), p.259-265

1998

Volltextzugriff (PDF)

Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine

Journal of investigative dermatology, 2010-10, Vol.130 (10), p.2514-2516

2010

Volltextzugriff (PDF)

Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide

Journal of Steroid Biochemistry, 1989-10, Vol.33 (4), p.565-571

1989

Volltextzugriff (PDF)

Aminoglutethimide and warfarin: a new important drug interaction

Cancer chemotherapy and pharmacology, 1984, Vol.12 (1), p.10-12

1984

Volltextzugriff (PDF)

Aminoglutethimide enzyme induction : pharmacological an endocrinological implications

Cancer chemotherapy and pharmacology, 1990-07, Vol.26 (4), p.241-244

LOÊNNING, P. E

1990

Volltextzugriff (PDF)

Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations

Acta oncologica, 2007, Vol.46 (2), p.199-203

2007

Volltextzugriff (PDF)

Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer

International journal of cancer, 1997-02, Vol.74 (1), p.138-140

1997

Volltextzugriff (PDF)

Antitumor efficacy improved by local delivery of species-specific endostatin

Journal of neurosurgery, 2006, Vol.104 (1), p.118-128

2006

Volltextzugriff (PDF)

APOBEC3A/B deletion polymorphism and endometrial cancer risk

Cancer medicine (Malden, MA), 2023-03, Vol.12 (6), p.6659-6667

2023

Volltextzugriff (PDF)

Are current development programs realising the full potential of new agents?

Breast cancer research : BCR, 2010-12, Vol.12 Suppl 4 (Suppl 4), p.S23-S23, Article S23

Lanning, Per Eystein

2010

Volltextzugriff (PDF)

Aromatase Inhibition for Breast Cancer Treatment

Acta oncologica, 1996, Vol.35 (S5), p.38-43

Loünning, Per E.

1996

Volltextzugriff (PDF)

Aromatase Inhibition: Translation into a Successful Therapeutic Approach

Clinical cancer research, 2005-04, Vol.11 (8), p.2809-2821

2005

Volltextzugriff (PDF)

Aromatase inhibitors and inactivators for breast cancer therapy

Drugs & aging, 2002, Vol.19 (4), p.277-298

LØNNING, Per E

2002

Volltextzugriff (PDF)

Aromatase inhibitors and inactivators in breast cancer

BMJ (Online), 2001-10, Vol.323 (7318), p.880

Lønning, P E

2001

Volltextzugriff (PDF)

Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?

The oncologist (Dayton, Ohio), 2008-08, Vol.13 (8), p.829-837

2008

Volltextzugriff (PDF)

Aromatase inhibitors as adjuvant treatment of breast cancer

Critical reviews in oncology/hematology, 2006, Vol.57 (1), p.53-61

2006

Volltextzugriff (PDF)

Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression

Journal of steroid biochemistry and molecular biology, 2008-02, Vol.108 (3), p.196-202

2008

Volltextzugriff (PDF)

Aromatase inhibitors in the treatment of early and advanced breast cancer

Acta oncologica, 2005-01, Vol.44 (1), p.23-31

2005

Volltextzugriff (PDF)

1 – 25 von 195

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(187)
Mit Volltextzugriff
(178)

Publikationsform

Artikel
(194)
Buchkapitel
(1)

Sprache

Norwegisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Abstract 1092: Alterations of the retinoblastoma gene in stage III breast cancers

Abstract 1792: MDM2 promoter variants and mRNA expression in irradiated lymphocytes

Abstract 3704: Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension in a single-arm Phase II study

Abstract CT010: Efficacy results based on PIK3CA status in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Alterations in the insulin-like growth factor system during the menstrual cycle in normal women

Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine

Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide

Aminoglutethimide and warfarin: a new important drug interaction

Aminoglutethimide enzyme induction : pharmacological an endocrinological implications

Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations

Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer

Antitumor efficacy improved by local delivery of species-specific endostatin

APOBEC3A/B deletion polymorphism and endometrial cancer risk

Are current development programs realising the full potential of new agents?

Aromatase Inhibition for Breast Cancer Treatment

Aromatase Inhibition: Translation into a Successful Therapeutic Approach

Aromatase inhibitors and inactivators for breast cancer therapy

Aromatase inhibitors and inactivators in breast cancer

Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?

Aromatase inhibitors as adjuvant treatment of breast cancer

Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression

Aromatase inhibitors in the treatment of early and advanced breast cancer

Aktive Filter

Suchergebnisse filtern